|Dr. Yakov N. Kogan Ph.D., MBA||Chief Exec. Officer and Interim Principal Financial Officer||287.47k||N/A||44|
|Dr. Langdon L. Miller M.D.||Pres and Chief Medical Officer||193.57k||N/A||63|
|Dr. Andrei V. Gudkov Ph.D., D.Sci.||Chief Scientific Officer||N/A||N/A||61|
|Dr. Ann Lenich Hards Ph.D.||Exec. VP of Regulatory Affairs||N/A||N/A||N/A|
|Dr. Andrei Purmal Ph.D.||VP of Chemistry||N/A||N/A||N/A|
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and the Russian Federation. The companys advanced product candidate is entolimod, a Toll-like receptor 5 (TLR5) agonist that is used to prevent death from acute radiation syndrome, and as an oncology drug. It is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. In addition, the company develops CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer. Cleveland BioLabs, Inc. has strategic partnerships with The Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.
Cleveland BioLabs, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.